Tekla Capital Management as of Dec. 31, 2013
Portfolio Holdings for Tekla Capital Management
Tekla Capital Management holds 57 positions in its portfolio as reported in the December 2013 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Gilead Sciences (GILD) | 11.9 | $113M | 1.5M | 75.15 | |
| Celgene Corporation | 9.1 | $86M | 510k | 168.96 | |
| Regeneron Pharmaceuticals (REGN) | 7.5 | $72M | 261k | 275.24 | |
| Biogen Idec (BIIB) | 5.6 | $54M | 192k | 279.75 | |
| Alexion Pharmaceuticals | 5.2 | $49M | 371k | 133.06 | |
| Amgen (AMGN) | 4.9 | $47M | 412k | 114.16 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.9 | $37M | 500k | 74.30 | |
| Actavis | 3.6 | $35M | 206k | 168.00 | |
| Perrigo Company (PRGO) | 3.6 | $34M | 221k | 153.46 | |
| iShares NASDAQ Biotechnology Index (IBB) | 3.2 | $31M | 136k | 227.06 | |
| Incyte Corporation (INCY) | 3.1 | $30M | 588k | 50.63 | |
| Akorn | 2.4 | $23M | 936k | 24.63 | |
| Shire | 2.3 | $22M | 154k | 141.29 | |
| Mylan | 2.2 | $21M | 488k | 43.40 | |
| Puma Biotechnology (PBYI) | 2.0 | $19M | 186k | 103.53 | |
| Allergan | 1.9 | $19M | 167k | 111.08 | |
| BioMarin Pharmaceutical (BMRN) | 1.9 | $18M | 258k | 70.27 | |
| Aetna | 1.8 | $17M | 247k | 68.59 | |
| Cubist Pharmaceuticals | 1.6 | $16M | 227k | 68.87 | |
| Alere | 1.4 | $13M | 370k | 36.20 | |
| Teva Pharmaceutical Industries (TEVA) | 1.3 | $13M | 312k | 40.08 | |
| Verastem | 1.2 | $12M | 1.0M | 11.40 | |
| Illumina (ILMN) | 1.2 | $12M | 104k | 110.62 | |
| Pharmacyclics | 1.1 | $10M | 98k | 105.78 | |
| Hologic (HOLX) | 1.0 | $9.9M | 445k | 22.35 | |
| McKesson Corporation (MCK) | 1.0 | $9.2M | 57k | 161.41 | |
| Ironwood Pharmaceuticals (IRWD) | 0.9 | $8.9M | 768k | 11.61 | |
| Forest Laboratories | 0.9 | $8.8M | 147k | 60.03 | |
| Impax Laboratories | 0.9 | $8.7M | 345k | 25.14 | |
| Endo Pharmaceuticals | 0.9 | $8.5M | 126k | 67.46 | |
| Sagent Pharmaceuticals | 0.8 | $8.1M | 319k | 25.38 | |
| Alkermes (ALKS) | 0.8 | $7.9M | 195k | 40.66 | |
| Catamaran | 0.7 | $6.9M | 146k | 47.48 | |
| Accuray Incorporated (ARAY) | 0.7 | $6.4M | 732k | 8.71 | |
| UnitedHealth (UNH) | 0.7 | $6.2M | 82k | 75.29 | |
| IDEXX Laboratories (IDXX) | 0.6 | $6.0M | 56k | 106.37 | |
| Intellipharmaceuticsintl Inc C | 0.6 | $5.2M | 1.4M | 3.70 | |
| Infinity Pharmaceuticals (INFIQ) | 0.5 | $4.8M | 350k | 13.81 | |
| Neurocrine Biosciences (NBIX) | 0.4 | $4.0M | 428k | 9.34 | |
| Merrimack Pharmaceuticals In | 0.4 | $4.0M | 757k | 5.34 | |
| CVS Caremark Corporation (CVS) | 0.4 | $3.8M | 54k | 71.57 | |
| Auxilium Pharmaceuticals | 0.4 | $3.6M | 173k | 20.74 | |
| Molina Healthcare (MOH) | 0.4 | $3.6M | 105k | 34.75 | |
| Centene Corporation (CNC) | 0.4 | $3.5M | 60k | 58.95 | |
| BioDelivery Sciences International | 0.4 | $3.4M | 582k | 5.89 | |
| Acorda Therapeutics | 0.3 | $3.3M | 113k | 29.20 | |
| Alnylam Pharmaceuticals (ALNY) | 0.3 | $3.1M | 49k | 64.34 | |
| Clovis Oncology | 0.2 | $2.0M | 33k | 60.26 | |
| Mei Pharma | 0.2 | $2.0M | 244k | 8.01 | |
| NPS Pharmaceuticals | 0.2 | $1.9M | 63k | 30.37 | |
| AVANIR Pharmaceuticals | 0.1 | $1.4M | 406k | 3.36 | |
| Thermo Fisher Scientific (TMO) | 0.1 | $1.1M | 10k | 111.32 | |
| PerkinElmer (RVTY) | 0.1 | $1.1M | 26k | 41.22 | |
| Supernus Pharmaceuticals (SUPN) | 0.1 | $1.1M | 141k | 7.54 | |
| Waters Corporation (WAT) | 0.1 | $970k | 9.7k | 100.00 | |
| OncoGenex Pharmaceuticals | 0.1 | $943k | 113k | 8.34 | |
| Macrogenics (MGNX) | 0.1 | $786k | 32k | 24.67 |
